| Multiple Myeloma
Mozobil vs Ninlaro
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Mozobil vs Ninlaro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNinlaro has a higher rate of injection site reactions vs Mozobil based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ninlaro but not Mozobil, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mozobil
Ninlaro
At A Glance
SC injection
Once daily for up to 4 days
CXCR4 antagonist
Oral
Once weekly (Days 1, 8, 15 of 28-day cycle)
Proteasome inhibitor
Indications
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Multiple Myeloma
Dosing
Lymphoma, Non-Hodgkin, Multiple Myeloma 0.24 mg/kg SC (or 20 mg fixed dose for patients <=83 kg) once daily approximately 11 hours prior to apheresis for up to 4 consecutive days, following filgrastim 10 mcg/kg once daily for 4 days; maximum 40 mg/day.
Renal Impairment (CrCl <=50 mL/min) Reduce dose by one-third to 0.16 mg/kg SC (or 13 mg fixed dose for patients <=83 kg); maximum 27 mg/day.
Multiple Myeloma 4 mg orally once weekly on Days 1, 8, and 15 of a 28-day cycle in combination with lenalidomide 25 mg daily (Days 1-21) and dexamethasone 40 mg (Days 1, 8, 15, 22); reduce starting dose to 3 mg for moderate or severe hepatic impairment, severe renal impairment (CrCl <30 mL/min), or ESRD requiring dialysis.
Contraindications
- History of hypersensitivity to plerixafor
—
Adverse Reactions
Most common (>=10%) Diarrhea, nausea, injection site reactions, fatigue, headache, arthralgia, dizziness, vomiting
Serious Anaphylactic shock, hypersensitivity reactions, tumor cell mobilization, hyperleukocytosis, decreased platelet counts, splenic enlargement
Postmarketing Splenomegaly, splenic rupture, anaphylactic reactions including anaphylactic shock, abnormal dreams and nightmares
Most common (>=20%) Thrombocytopenia, neutropenia, diarrhea, constipation, peripheral neuropathy, nausea, peripheral edema, rash, vomiting, bronchitis
Serious Diarrhea, thrombocytopenia, bronchitis
Postmarketing Angioedema, toxic epidermal necrolysis
Pharmacology
Plerixafor is a CXCR4 chemokine receptor inhibitor that blocks binding of stromal cell-derived factor-1alpha (SDF-1alpha), disrupting HSC anchoring in the bone marrow and mobilizing hematopoietic stem cells to the peripheral blood for apheresis collection.
Ixazomib is a reversible proteasome inhibitor that preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome, inducing apoptosis in multiple myeloma cell lines and demonstrating synergistic cytotoxic effects in combination with lenalidomide.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mozobil
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Ninlaro
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Mozobil
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Ninlaro
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Mozobil
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Ninlaro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Chemotherapy Induced Neutropenia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Multiple Myeloma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MozobilView full Mozobil profile
NinlaroView full Ninlaro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.